2022 promises to be a progressive year for therapeutic psych 2022 promises to be a progressive year for therapeutic psychedelics companies like Origin Therapeutics $ORIG
2021 was a milestone year for psychedelic therapy, and 2022 promises to be even more progressive in North America, with Canada kicking off the new year on a high note.
Health Canada will allow physicians to request patient access to illegal psychoactive substances, like MDMA and psilocybin, for psychedelic-assisted therapy. Decisions will remain on a case-by-case basis and will be reserved for serious treatment-resistant or life-threatening conditions, in instances where other therapies have failed, are unsuitable or are not available in Canada. This amendment is a reversal of a 2013 Health Canada policy that prevented “a letter of authorization for a new drug that is or that contains a restricted drug.”
This is a huge step forward for the industry and highlights the increasing value of companies like Origin Therapeutics.
Origin is expected to go public on the CSE this year under the ticker $ORIG. With regulations continuing to trend towards the normalization of these novel therapies, the therapeutic psychedelic industry should start to see an acceleration in growth.
https://psychedelicspotlight.com/health-canada-psychedelic-therapy-special-access-programme-amendment/#:~:text=Health%20Canada%20Grants%20Special%20Access%20to%20Restricted%20Drugs%20for%20Psychedelic%20Therapy&text=New%20amendment%20reverses%20a%202013,that%20contains%20a%20restricted%20drug.%22